[Patient with Epstein-Barr Virus-Positive Esophagogastric Junctional Cancer with Splenic Metastasis and Underwent Metastasectomy following Immune Checkpoint Therapy].

Abstract

Recurrent gastric cancer(GC)with splenic metastasis showed poor prognosis, and its treatment strategy remains unclear. Recently, studies identified the considerable prognostic effect of metastasectomy in GC following intensive chemotherapy. Here, we successfully treated a patient with Epstein-Barr virus-positive esophagogastric junctional cancer with splenic metastasis who underwent metastasectomy and obtained pathological complete response following immune checkpoint therapy and had long-term survival. We reviewed the literature to discuss the clinical significance of our treatment strategy.

• Authors: Haruna Ogawa, Shuhei Komatsu, Daiki Matsubara, Satoshi Hamada, Mizuki Nishiko, Tomoki Konishi, Koji Soga, Jun Ikeda, Katsumi Shimomura, Fumihiro Taniguchi, Yasuhiro Shioaki
• Journal: Gan to kagaku ryoho. Cancer & chemotherapy (Gan To Kagaku Ryoho) Vol. 49 Issue 10 Pg. 1163-1165 (Oct 2022) ISSN: 0385-0684 [Print] Japan
• PMID: 36281620 (Publication Type: Review, English Abstract, Journal Article)

Topics

• Humans
• Metastasectomy
• Herpesvirus 4, Human
• Epstein-Barr Virus Infections (complications)
• Splenic Neoplasms (surgery)
• Neoplasm Recurrence, Local
• Prognosis
• Stomach Neoplasms (drug therapy, surgery)
• Neoplasms, Second Primary